AbstractAimTo evaluate the Klarity® Mask with respect to skin doses and toxicity secondary to head and neck cancer radiation treatment.Materials and methodsThis prospective study included five nasopharyngeal cancer patients who underwent intensity-modulated radiation therapy and monitored for skin toxicity. An anatomical Perspex head and neck phantom was designed and used. All patients’ treatment plans were separately transferred to the phantom. Dosimetric measurements were performed using chip-shaped thermoluminescent dosimeters (LiF:Mg,Ti TLDs) which were distributed at certain target points on the phantom. Phantom was irradiated twicely with and without a Klarity® Mask. Three fractions for each patient plan were obtained and compared with treatment planning system (TPS) doses as guided by computed tomography.ResultsThe Klarity mask used for patient immobilisation increased the surface dose by 10·83% more than that without the mask. The average variations between skin dose measurements with and without the Klarity mask for all patients’ plans ranged from 10·26 to 11·83%. TPS overestimated the surface dose by 19·13% when compared with thermoluminescent dosimeters that measured the direct skin dose.ConclusionsKlarity immobilisation mask increases skin doses, as a consequence, surface dose measurements should be monitored and must be taken into account.
Optimization of skin dose using in-vivo
MOSFET dose measurements in bolus/non-bolus fraction ratio: A VMAT and a 3DCRT study
